How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Still looking? See more results on Wirecutter. We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By James Austin James Austin is a ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals reported 5 insider transactions totaling $528,153.30. Activity split between 3 Tax Payments worth $351,830.92 and 2 Sales worth $176,322.38. Ben R Taylor and Najat Khan ...